Pages
Products
Support
CBpromise

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER

Genes

CTLA-4 and PD-1 Blockade in Cancer Immunotherapy

CTLA-4 and PD-1 Blockade in Cancer Immunotherapy

The potential of T cells to attack and destroy tumors has long been recognized. Recent experimental evidence has also demonstrated that T cell surveillance throughout the life of an organism functions to prevent tumor development.

Research of Agonistic CD40 Antibodies in The Mechanism of Action of Cancer Immunotherapy

Research of Agonistic CD40 Antibodies in The Mechanism of Action of Cancer Immunotherapy

Immunotherapy is an emerging alternative or adjunct to traditional cancer therapies, its goal being to stimulate a potent and specific anti-tumor immune response. The agonistic anti-CD40 monoclonal antibody is one of the most promising immunotherapies tried so far in animal models.

Research of The Role of PD-1/PD-L1 Pathway in Cancer

Research of The Role of PD-1/PD-L1 Pathway in Cancer

Tumor cells can escape the immune surveillance and disrupt immune checkpoint of host in several methods, therefore, to avoid the elimination from the host immune system. Numerous pathways are utilized by cancers to up-regulate the negative signals through cell surface molecules.

Research of TRPV1 in Drug Discovery: Targeting Pain and Other Pathological Disorders

Research of TRPV1 in Drug Discovery: Targeting Pain and Other Pathological Disorders

Chronic pain affects a large segment of the population, an estimated 50 million Americans, and costs the country billions of dollars in health care costs and lost productivity. Although the Decade of Pain Control and Research has given new impetus to pain research, the translation of preclinical research into clinical practice is slow to occur.

TRPV1 in Drug Discovery: Targeting Pain and Other Pathological Disorders

TRPV1 in Drug Discovery: Targeting Pain and Other Pathological Disorders

TRPV1, the founding member of the 'vanilloid' TRP subfamily, is formerly known as the vanilloid receptor VR1. Vanilloid, because of its archetypal activators, capsaicin and resiniferatoxin, shares a vanillyl moiety essential for bioactivity.